Trials / Enrolling By Invitation
Enrolling By InvitationNCT06931613
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment With or Without Bendamustine
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- St. Petersburg State Pavlov Medical University · Academic / Other
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.
Conditions
- Relapsed or Refractory Hodgkin Lymphoma
- Children
- Nivolumab
- Autologous Haemopoietic Stem Cell Transplant
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Nivolumab with or without bendamustine is administered to children prior to auto-HSCT |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
- First posted
- 2025-04-17
- Last updated
- 2025-04-17
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT06931613. Inclusion in this directory is not an endorsement.